124 related articles for article (PubMed ID: 12089373)
1. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.
Cao Z; Bonnet F; Candido R; Nesteroff SP; Burns WC; Kawachi H; Shimizu F; Carey RM; De Gasparo M; Cooper ME
J Am Soc Nephrol; 2002 Jul; 13(7):1773-87. PubMed ID: 12089373
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis.
Cao Z; Kelly DJ; Cox A; Casley D; Forbes JM; Martinello P; Dean R; Gilbert RE; Cooper ME
Kidney Int; 2000 Dec; 58(6):2437-51. PubMed ID: 11115077
[TBL] [Abstract][Full Text] [Related]
3. Increased osteopontin expression following renal ablation is attenuated by angiotensin type 1 receptor antagonism.
Cao Z; Cox A; Bonnet F
Exp Nephrol; 2002; 10(1):19-25. PubMed ID: 11803201
[TBL] [Abstract][Full Text] [Related]
4. Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis.
Madrid MI; García-Salom M; Tornel J; De Gasparo M; Fenoy FJ
Am J Physiol; 1997 Nov; 273(5):R1676-82. PubMed ID: 9374809
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II.
Yu XQ; Wu LL; Huang XR; Yang N; Gilbert RE; Cooper ME; Johnson RJ; Lai KN; Lan HY
Kidney Int; 2000 Oct; 58(4):1469-80. PubMed ID: 11012882
[TBL] [Abstract][Full Text] [Related]
6. Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
Siragy HM; El-Kersh MA; De Gasparo M; Webb RL; Carey RM
J Hypertens; 2002 Jun; 20(6):1157-63. PubMed ID: 12023686
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation.
Hilgers KF; Hartner A; Porst M; Veelken R; Mann JF
Circulation; 2001 Sep; 104(12):1436-40. PubMed ID: 11560862
[TBL] [Abstract][Full Text] [Related]
8. Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
Abdel-Rahman EM; Abadir PM; Siragy HM
Am J Physiol Regul Integr Comp Physiol; 2008 Nov; 295(5):R1473-8. PubMed ID: 18799632
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
Abadir PM; Carey RM; Siragy HM
Hypertension; 2003 Oct; 42(4):600-4. PubMed ID: 12953015
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
11. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury.
Hilgers KF; Hartner A; Porst M; Mai M; Wittmann M; Hugo C; Ganten D; Geiger H; Veelken R; Mann JF
Kidney Int; 2000 Dec; 58(6):2408-19. PubMed ID: 11115074
[TBL] [Abstract][Full Text] [Related]
12. Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system.
Wu LL; Cox A; Roe CJ; Dziadek M; Cooper ME; Gilbert RE
J Am Soc Nephrol; 1997 Sep; 8(9):1373-82. PubMed ID: 9294828
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
Cao Z; Cooper ME; Wu LL; Cox AJ; Jandeleit-Dahm K; Kelly DJ; Gilbert RE
Hypertension; 2000 Oct; 36(4):561-8. PubMed ID: 11040236
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
Siragy HM; de Gasparo M; El-Kersh M; Carey RM
Hypertension; 2001 Aug; 38(2):183-6. PubMed ID: 11509473
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
16. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
[TBL] [Abstract][Full Text] [Related]
17. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.
Sandmann S; Yu M; Unger T
Br J Pharmacol; 2001 Feb; 132(3):767-77. PubMed ID: 11159730
[TBL] [Abstract][Full Text] [Related]
20. [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
Zhang C; Chen YP; Dong HR; Qiu CB
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(37):2601-6. PubMed ID: 16321319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
